Madrigal Pharmaceuticals (MDGL) Leads Healthcare CapEx Growth Amid Elevated Price-to-Sales Valuation

gurufocus.com · 2026-09-02

On September 02, 2026, as the second-quarter earnings season wrapped up, Madrigal Pharmaceuticals, Inc. (MDGL) stood out with a remarkable 779.77% year-over-yea

TickrTrends take: Alnylam Pharmaceuticals operates in the same Healthcare sector as Madrigal Pharmaceuticals, where capital expenditure growth patterns can signal shifting competitive dynamics and investor appetite for the industry. TickrTrends is currently awaiting full valuation data for ALNY, meaning investors watching this stock should monitor whether healthcare companies' elevated price-to-sales multiples persist or normalize as the sector's capital spending cycle evolves. Understanding where ALNY sits relative to peers experiencing significant CapEx growth will be important context once its full valuation profile becomes available.

Read the full story at gurufocus.com →